.jpg?format=webp&width=780)
Metalloproteinases include a disintegrin and metalloprotease (ADAM), which were previously examined using a fluorescence assay system and described their association with resistance to systemic therapy in cancer patients. Inhibiting their immunomodulating activity in chronic inflammation restores innate immunity and potentially prevents the development of various cancers. This review summarizes our current understanding of the role of ADAMs in gastroenterological diseases with regard to the immune system. In addition, several Food and Drug Administration (FDA) approved inhibitors of ADAMs have been identified, and potential therapies for targeting ADAMs in treating chronic inflammatory diseases and cancers are discussed.
Like
Save
Share